Investors

Press Releases

Press Releases

Press Releases

Oct 09, 2020
Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa
Data to be presented at the 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA) Results support clinical development of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS) and other IL-1R/TLR-driven autoimmune and inflammatory diseases , with Phase 1 trial on track for
PDF Version
Jun 11, 2020
Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
Data to be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II Cambridge, Mass. (June 11, 2020) – Kymera Therapeutics, Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients,
PDF Version
Displaying 1 - 10 of 12

Investor Contact

Bruce Jacobs
Chief Financial Officer
investors@kymeratx.com
+1 857.285.5300

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com 
+ 1 339.970.2843
 

Media Contact

media@kymeratx.com

Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
+1 202.930.4762

Sign Up for Email Alerts